Researchers develop Ebola treatment effective three days after infection

April 22, 2015, University of Texas Medical Branch at Galveston
Lead UTMB author Thomas Geisbert. Credit: The University of Texas Medical Branch at Galveston

Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa.

The study results, in the April 22 edition of Nature journal, demonstrated that the treatment is the first to be shown effective against the new Makona outbreak strain of Ebola in animals that were infected with the virus and exhibited symptoms of the disease.

The treatment uses a sequence specific short strand of RNA, known as siRNA, designed to target and interfere with the Ebola virus, rendering it harmless. One of the advantages of this approach is the ability to quickly modify it to different viral strains.

"We quickly adapted our candidate treatment to target the Makona outbreak strain of Ebola virus," said UTMB's Thomas Geisbert, professor of microbiology and immunology. "We were able to protect all of our nonhuman primates against a lethal Makona Ebola infection when treatment began three days following infection. At this point, those infected showed clinical signs of disease and had detectable levels of virus in their blood."

Although all infected animals showed evidence of advanced disease, those receiving treatment had milder symptoms and recovered fully. The untreated controls succumbed to the disease on days eight and nine, which is similar to that reported in the field after patients begin showing symptoms of Ebola.

This treatment also protected against liver and kidney dysfunction and blood disorders that occur during an Ebola infection. These results indicate that the may confer protective benefits that go beyond improving survival rates and effective control of virus levels in the body.

"This study demonstrates that we can rapidly and accurately adapt our siRNA-LNP technology to target genetic sequences emerging from new Ebola outbreaks," said Dr. Mark Murray, president and CEO of Tekmira Pharmaceuticals.

The Tekmira siRNA-based therapeutic is now being evaluated in Ebola-infected patients in Sierra Leone.

Explore further: Researchers develop Ebola vaccine effective in a single dose

More information: Nature, DOI: 10.1038/nature14442

Related Stories

Researchers develop Ebola vaccine effective in a single dose

April 8, 2015
An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola ...

Tekmira will resume safety study of Ebola drug within weeks

April 10, 2015
Canadian drugmaker Tekmira Pharmaceuticals said Friday it will restart a study of an experimental Ebola treatment in the coming weeks.

Team develops treatment effective against lethal Marburg virus

August 20, 2014
For the first time, researchers at the University of Texas Medical Branch at Galveston, in collaboration with Tekmira Pharmaceuticals, have protected nonhuman primates against Marburg virus – Angola hemorrhagic fever. Their ...

US Ebola patient's condition improves: NIH

March 26, 2015
An American healthcare worker in treatment after becoming infected with the Ebola virus in Sierra Leone has improved and is now in serious condition, the National Institutes of Health said Thursday.

Leading Ebola researcher says there's an effective treatment

August 29, 2014
A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola ...

Ebola vaccine trial begins in Sierra Leone

April 14, 2015
Thousands of healthcare workers in areas of Sierra Leone that are grappling with Ebola will now begin receiving an experimental vaccine against the often deadly virus, officials said Tuesday.

Recommended for you

Research finds new mechanism that can cause the spread of deadly infection

April 20, 2018
Scientists at the University of Birmingham have discovered a unique mechanism that drives the spread of a deadly infection.

Selection of a pyrethroid metabolic enzyme CYP9K1 by malaria control activities

April 20, 2018
Researchers from LSTM, with partners from a number of international institutions, have shown the rapid selection of a novel P450 enzyme leading to insecticide resistance in a major malaria vector.

Low-cost anti-hookworm drug boosts female farmers' physical fitness

April 19, 2018
Impoverished female farm workers infected with intestinal parasites known as hookworms saw significant improvements in physical fitness when they were treated with a low-cost deworming drug. The benefits were seen even in ...

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

Super-superbug clones invade Gulf States

April 18, 2018
A new wave of highly antibiotic resistant superbugs has been found in the Middle East Gulf States, discovered by University of Queensland researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.